Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273124 | 0.97 | LMNA (0.49) | LMNAMAPTMAPK1ACE2DGKA | |
| SCHEMBL1739619 | 0.92 | LMNA (0.53) | LMNAMAPTMAPK1ACE2DGKA | |
| SCHEMBL1740609 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL28898399 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL28745605 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL8340752 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL29124961 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL22655191 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL7802146 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 | |
| SCHEMBL29061964 | 0.90 | LMNA (0.58) | LMNAMAPTMAPK1DGKAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2023-05-11 | — | — | US | claimed |
| EP-3636259-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-04-15 | — | — | EP | claimed |
| EP-2737901-A1 | Therapeutic Use of Compounds | UCL Business PLC (GB) | 2014-06-04 | — | — | EP | claimed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | claimed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | LMNA 693/4885MAPT 3777/4885MAPK1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.